As expected, treatment of tumor-bearing mice with EPO resulted in a marked increase in hematocrit by the end of the study period when compared to PBS-injected control animals (56.9 ± 1.9% vs. 39.8 ± 1.38% ; Figure 1B) and to a level comparable to that of naïve mice. The gene discussed is EPO; the disease is neoplasm.